CBDV belongs to the cannabidivarin series of compounds first isolated and characterised in the 1960s. Its structural distinction from CBD lies at the alkyl side chain: where CBD carries a five-carbon (pentyl) chain, CBDV carries a three-carbon (propyl) chain. This seemingly minor difference alters the molecule's binding geometry and pharmacokinetic profile. CBDV tends to occur at higher concentrations in certain landrace cannabis varieties , particularly those originating from northwest India and Pakistan , and in plants with naturally elevated CBD-to-THC ratios.
At the receptor level, CBDV shows relatively low binding affinity for the classical cannabinoid receptors CB1 and CB2. Research attention has instead focused on its interactions with transient receptor potential (TRP) ion channels, particularly TRPV1, TRPA1, and TRPM8, where it has demonstrated desensitising activity in preclinical models. CBDV has also been identified as a modulator of the endocannabinoid system's enzymatic machinery, with some in vitro evidence of interaction with diacylglycerol lipase (DAGL) and other biosynthetic enzymes.
Preclinical research , principally in rodent models; has examined CBDV's pharmacological profile across several areas, including its effects on neuronal excitability and gastrointestinal muscle contractility. A small number of early-phase human clinical trials have been conducted, registered on publicly searchable trial databases, though results to date are preliminary and study populations have been limited in size. No regulatory agency has approved CBDV as a medicine in Australia; it is not currently listed on the Australian Register of Therapeutic Goods (ARTG) as a standalone approved product. Access to any CBDV-containing preparation in a clinical context would be subject to the Therapeutic Goods Administration's Special Access Scheme (SAS) or Authorised Prescriber pathways under the Therapeutic Goods Act 1989.
Under Australia's Poisons Standard (the Standard for the Uniform Scheduling of Medicines and Poisons), cannabinoids derived from cannabis are regulated substances. CBDV's scheduling classification depends on its source, concentration, and intended use; researchers and clinicians should consult the current Poisons Standard and TGA guidance directly, as scheduling determinations are subject to revision.
Sources:
- Cannabidivarin, PubChem, National Center for Biotechnology Information (NCBI)
- Cannabidiol scheduling and regulatory guidance, Therapeutic Goods Administration (TGA)
- Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism; British Journal of Pharmacology (PMC)